{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Two new studies reported in preliminary form yesterday suggest that a second drug can apparently prevent breast cancer, at least in the short term. But this drug, raloxifene, did not appear to raise the risk of uterine cancer, a side effect of the first drug, tamoxifen, whose benefits were reported earlier this month. Raloxifene reduced the incidence of breast cancer by about half, roughly the same proportion as in the earlier study of tamoxifen, according to information made public yesterday by a national cancer organization. However, the raloxifene studies did not last as long as the tamoxifen study.", "headline": {"main": "Studies Show Another Drug Can Prevent Breast Cancer"}, "abstract": "Preliminary findings by researchers at Robert H Lurie Cancer Center in Chicago and at University of California suggest second drug, raloxifene, can apparently prevent breast cancer, at least in short term, and does not appear to raise risk of uterine cancer as tamoxifen, whose benefits were reported earlier; drug reduced incidence of cancer by about half, as in earlier study of tamoxifen; studies were conducted at medical centers in US and Europe on thousands of post-menopausal women and were sponsored by Eli Lilly & Co, raloxifene's manufacturer (M)", "print_page": "16", "word_count": 854, "_id": "4fd216c68eb7c8105d791c9a", "snippet": "Two new studies reported in preliminary form yesterday suggest that a second drug can apparently prevent breast cancer, at least in the short term. But this drug, raloxifene, did not appear to raise the risk of uterine cancer, a side effect of the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1998/04/21/us/studies-show-another-drug-can-prevent-breast-cancer.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "RALOXIFENE"}, {"name": "organizations", "value": "LILLY, ELI, & CO"}, {"name": "organizations", "value": "LURIE, ROBERT H, CANCER CENTER"}, {"name": "organizations", "value": "UNIVERSITY OF CALIFORNIA"}, {"name": "subject", "value": "BREAST"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "WOMEN"}, {"name": "subject", "value": "MENOPAUSE"}, {"name": "subject", "value": "TAMOXIFEN (DRUG)"}], "byline": {"person": [{"firstname": "Lawrence", "middlename": "K.", "lastname": "ALTMAN", "rank": 1, "role": "reported", "organization": ""}], "original": "By LAWRENCE K. ALTMAN"}, "document_type": "article", "pub_date": "1998-04-21T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "In only its second week on the market, Viagra, Pfizer's impotence drug, accounted for 79.2 percent of the new prescriptions written for the condition, causing the market shares of its competitors to plunge, according to I.M.S. America, a health care information company. With 36,263 new prescriptions for Viagra written in the week that ended on April 10, the latest for which statistics were available, the introduction of Viagra was one of the best of all time for a drug.", "headline": {"main": "Pfizer Drug For Impotence Leads Market"}, "abstract": "IMS America says in only its second week on the market, Viagra, Pfizer Inc's impotence drug, accounted for 79.2 percent of new prescriptions written for condition; 36,263 new prescriptions for Viagra were written in week ended April 10; graph (L)", "print_page": "1", "word_count": 962, "_id": "4fd1fb418eb7c8105d759704", "snippet": "In only its second week on the market, Viagra, Pfizer's impotence drug, accounted for 79.2 percent of the new prescriptions written for the condition, causing the market shares of its competitors to plunge, according to I.M.S. America, a health care...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1998/04/21/business/pfizer-drug-for-impotence-leads-market.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "VIVUS INC"}, {"name": "organizations", "value": "PHARMACIA & UPJOHN INC"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "IMS AMERICA"}, {"name": "subject", "value": "SEX"}, {"name": "subject", "value": "IMPOTENCE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "VIAGRA (DRUG)"}], "byline": {"person": [{"firstname": "David", "middlename": "J.", "lastname": "MORROW", "rank": 1, "role": "reported", "organization": ""}], "original": "By DAVID J. MORROW"}, "document_type": "article", "pub_date": "1998-04-21T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 2, "offset": 0, "time": 255}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}